|
Name:
James Robert Bentley
Home Address:
39 Pinehaven Drive
Halifax, NS
B3P 1Y9
Tel: (902) 446 5214
Work Address:
Dickson Building, Room 5006
5820 University Avenue
Halifax, NS
B3H 1V7
Tel: (902) 473 4029
Cell: (902) 452 3894
Fax: (902) 473 7765
E-mail: jim.bentley@dal.ca
Place/Date of Birth:
Derby, UK; 31st October 1963
Civil Status:
Married, wife Bettina
Children:
Two daughters, Victoria 20, Heidi 18
Citizenship:
Canadian
Education
Degrees:
MBChB Leeds University UK 1987
Specialist Certification:
FRCSC Obstetrics and Gynecology 1997
FRCSC Gynecologic Oncology 1999
Post Graduate Training:
Pre-registration year: Six months Internal Medicine, Bradford Royal Infirmary, three months Urology and three months General Surgery, St James University Hospital Leeds UK August 1987- July 1988
Senior House Officer in Emergency Medicine: August 1988- December 1988, North Manchester General, Manchester, UK
Resident in General Surgery: January 1989- December 1989, Charles S. Curtis Memorial Hospital, St Anthony, Newfoundland
Resident in Obstetrics and Gynecology: January 1990-March 1990, Charles S. Curtis Memorial Hospital, St Anthony, Newfoundland
Upgrading Internship: February 1991- July 1991, Memorial University of Newfoundland
Residency in Obstetrics and Gynecology: July 1993- June 1997, Dalhousie University, Halifax, Nova Scotia
Fellowship in Gynecologic Oncology: July 1997- June 1999, University of Manitoba, Winnipeg, Manitoba
Awards
CREOG Award for Residency teaching, Dalhousie University 2000
APOG Carl Nimrod Teaching Award 2007
Dr. Lea C Steeves Award for CME, Dalhousie University 2009
Professional/Academic Experience:
Active Staff, Dr Hugh Twomey Health Care Centre, Botwood, Newfoundland. April 1990- June 1993
Member Gynecology Tumour Site Group, Nova Scotia Cancer Centre, July 1999 to present
Active Staff, Dept. Gynecology, QEII Health Sciences Centre, July 1999 to present
Active Staff, Dept. Obstetrics and Gynecology, IWK/Grace Hospital, July 1999 to present
Consulting Staff, Cape Breton Regional Hospital, July 1999 to present
Assistant Professor, Obstetrics and Gynecology, Dalhousie University, July 1999 to June 2004
Associate Professor, Obstetrics and Gynecology, Dalhousie University, July 2004 to June 2009
Professor, Obstetrics and Gynecology, Dalhousie University, July 2009 to present
Professional Memberships:
Member, Society of Obstetricians and Gynecologists of Canada (SOGC) 1999 to present
Fellow, Royal College of Physicians and Surgeons of Canada 1997 to present
Member, Gynecologic Oncologists of Canada (GOC), July 1999 to present
Member, International Society Gynecologic Oncology, March 2000 to present
Member, Society of Canadian Colposcopists, July 2001 to present
Committee Memberships/Administrative Activities:
Departmental:
Post-graduate Resident Education Committee Member, July 1999 to present
Gynecologic Oncology Post-Graduate Resident Education
Director, July 1999 to July 2006
Director of Colposcopy, July 1999 to present
Colposcopy Resident Education Director July 1999 till present
Director of Laparoscopy, Division of Gynecologic Oncology, July 1999 to present
Member Clinical Appraisal Committee, QEII Health Sciences Centre, May 2000 to June 2002
Member Advisory Group for Physician Needs Assessment in Cancer Education, February 2001 to June 2002
Member interview committee, Residency Program Dept Obstetrics and Gynecology 2002, 2006, 2007
Member Survey and Search Committee, Chair of Pathology, June 2002- 2003
Member Promotions and Tenure Committee, Dept of Obstetrics and Gynecology, Sept 2005-2008
Member Departmental Advisory Committee, Dept Obstetrics and Gynecology, May 2008-present
Member OR Executive QEII HSC, May 2008-present
Member OR Committee VG Site QEII HSC, May 2008-present
Member Clinical Affairs Committee QEII HC July 2008-present
Chair Gynecologic Oncology Site Group, Cancer Care Nova Scotia and CDHA, May 2008-present
Division Head, Division of Gynecologic Oncology, CDHA and Dalhousie University, May 2008 –present
Member Oncology Therapy Subcommittee, QEII HSC May 2010-present
University:
Interviewer prospective medical students 2006, 2009
Provincial:
Nova Scotia Gestational Trophoblastic Disease Registry, Head, July 1999 to present
Member Steering Committee NSGCP, Jan 2000 to 2005
Member Management Committee NSCCPP 2005 to present
Chairman Colposcopy subcommittee NSGCP/ NSCCPP, Jan 2000 to present
Member Advisory Committee on HPV Immunization 2007
Member Provincial Systemic Therapy Coordinating Committee, April 2009-present
National
Member Executive Committee, Society of Canadian Colposcopists, July 2001 to present
AGM Course Director, Society of Canadian Colposcopists, July 2002 to June 2005
President Elect, Society of Canadian Colposcopists, June 2005 to June 2007
President, Society of Canadian Colposcopy June 2007 to June 2009
Member ACM Planning Committee SOGC 2003, 2004, 2005
Member Specialty Committee Gynecologic Oncology, Royal College of Physicians and Surgeons of Canada, June 2002 till present
Vice –Chair Specialty Committee Gynecologic Oncology, Royal College of Physicians and Surgeons of Canada, June 2007 till present
Member Examination Committee Gynecologic Oncology, Royal College of Physicians and Surgeons of Canada, June 2008 till present
Member Membership Committee, Gynecologic Oncologists of Canada, June 2003 till June 2005
Member Community of Practice Committee on IP chemotherapy, Gynecologic Oncologist of Canada Jan 2006 till present
Member HPV Awareness Committee SOGC April 2006 to present
Member SOGC, SCC, GOC Clinical Practice Guidelines Committee, June 2006 to present
Member GOC Task Force on Cervical Cancer Prevention and Control, June 2006 to present
Member Advisory Committee: Contemporary clinical questions on HPV vaccination. GOC in association with SCC Nov 2006- May 2007
Member Board of Directors, Canadian Foundation for Women’s Health, Nov 2007- present
Examiner and Member of Exam Board RCPSC Obstetrics and Gynecology June 2009-present
Member Steering Group Canadian Network on HPV prevention, Nov 2009- present
Member CPD Committee GOC May 2009-present
International:
Treasurer International Federation of Colposcopy and Cervical Pathology, Oct 2008 till present
Member Nomenclature Committee International Federation of Colposcopy and Cervical Pathology Oct 2008 till present
Research:
1. Investigator, OVA-Gy-06-A Multi-centre phase IIb clinical trial of Ovarex Mab-B43.13 vs, placebo for the consolidation therapy of advanced ovarian cancer
$34,000
2. Investigator NESP-980291 -A randomized dose finding trial of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients with solid tumors receiving chemotherapy
3. Investigator NCIC CTG EN.5 -A Phase III randomized trial comparing TAHBSO vs. TAHBSO plus adjuvant pelvic irradiation in Stage I (intermediate risk) carcinoma of the endometrium
4. Investigator NCIC-CTG OV.13 – An International multi-centre, randomized phase III study comparing upfront debulking surgery vs. neo-adjuvant chemotherapy in patients with stage IIIC or IV epithelial ovarian cancer
5. Investigator NCIC-CTG OV.14 – An International randomized phase III trial of Paclitaxel/Epirubicin/Carboplatin (TEC) vs. Paclitaxel/Carboplatin (TC) in the initial treatment of women with advanced epithelial ovarian cancer
6. Investigator IND 138: A Randomized phase II study of NX211 given by two different intravenous schedules in advanced and/ or recurrent epithelial cancer
7. Centre Principle Investigator: NCIC-CTG OV15 – A randomized trial of Gemcitabine and Carboplatin vs. Carboplatin in recurrent Ovarian Cancer
$23,551
8. Centre Principle Investigator: A Randomized Trial of Immediate Treatment vs. Colposcopic Follow-up for Biopsy proven CIN 1
9. Centre Principle Investigator: NCIC-CTG GTN1- A randomised trial of Methotrexate vs. Actinomycin D in low risk Gestational Trophoblastic Disease
$10,800
10. Investigator: NCIC-CTG OV16- A randomized trial of Topotecan/ Cisplatin/ Taxol/ Carboplatin vs. Carboplatin and Taxol in stage III or IV Ovarian Cancer
11. Investigator NCIC IND. 149: A Phase II study of OSI-774 in combination with carboplatin in patients with recurrent epithelial ovarian cancer
12. Investigator: Identification of Circulating and Excreted Proteins based on their expression in mullarian lesions as determined by the pathological evaluation of tissue. PI: Dr’s SC Murray and A Guha, Dept of Pathology
13. Centre Principle Investigator: Schering- Carboplatin and Caelyx in Recurrent Ovarian Cancer
$39,650
14. Investigator: HPV-015 – A Phase III, double-blind, randomized, controlled study to evaluate HPV L1 HPV 16/18 vaccine in women over 26
GSK- $270,000
15. Centre Principle Investigator: NCIC-CTG OV17- A Randomized trial of Caelyx/ Carboplatin vs. Carboplatin and Taxol in Platinum Sensitive Ovarian Cancer
$30,000
16. Investigator NCIC IND. 160: Phase II study of CCI-779 in patients with metastatic and/or locally advanced recurrent endometrial cancer
17. Centre Principle Investigator: TPAPT Study, Investigating New Markers in Cervical Carcinogenesis
Unrestricted grant Merck-$ 176,647.50
18. Investigator NCIC IND.185: Sunitinib for Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma
19. Investigator: A Phase II Randomised Study for FOCUS: Fragmin in Ovarian Cancer: Utility on Survival
20. Investigator: Key Determinants of Canadian Healthcare Professionals Willingness to Recommend Human Papillomavirus vaccine
Unrestricted grant GSK-$225,000
21. Investigator: Examination of cellular alterations in ovarian cancer. PI: Dr M Nachtigal, Dept of Pharmacology
22. Investigator: Study of Treatment Patterns and Cost of Care of Abnormal Cervical Lesions
23. Investigator: Key Determinants of Canadian Parents and Adolescents Willingness to accept Human Papillomavirus vaccination
24. Investigator: NCIC OV 19: (ICON7) A randomized, two arm, multi-center Gynecologic Cancer Intergroup trial of adding bevacizumab to standard chemotherapy in patients with epithelial ovarian cancer
25. Investigator: A randomized, Double-blind, Placebo Controlled, Phase 2 Trial of Paclitaxel in Combination with AMG 386 in Subjects with Advanced Recurrent Epithelial Ovarian or Primary Peritoneal Cancer
$64000
26. Investigator: GROINSS; GROningen INternatonal Study on Sentinel nodes in Vulvar cancer
27. Investigator: V503-001: A Randomized, International, Double-Blinded, Controlled with GARDASIL, Dose-Ranging, Tolerability, Immunogenicity, and Efficacy Study of a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Administration to 16- to 26- Year-Old Women
Merck
28. Investigator: NCIC EN7 (PORTEC 3): A randomised, international, trial, comparing radiation to radiation and chemotherapy in high risk endometrial cancer.
29. Centre Principle Investigator: Ixample2: A trial of CA163196 (Ixapilone) in Recurrent Endometrial Cancer
30. Investigator OV21:A Phase II/III Study of Intraperitoneal (IP) plus Intravenous (IV) Chemotherapy vs Carboplatin plus Paclitaxel in Patients with Epithelial Ovarian Cancer Optimally Debulked at Surgery Following Neoadjuvant Intravenous Chemotherapy
31. Centre Principle Investigator: CoHIPP Study; Colposcopy vs. HPV testing to Identify Persistent Precancers
Supervised Research Projects:
1. Dr K Keiser, Resident O &G: Stage 1 Leiomyosarcoma of the uterus. 2000
2. Dr S Samson, Resident O &G: LEEP and future pregnancy. 2000-2005
Atlee Grant: $5000
3. Ms D Mackay, Med III: LEEP and future pregnancy
Alternative modalities in gynecologic cancer
Nora Stevens Oncology Scholarship: $4500
4. Dr C Hamm, Resident O &G: Laparoscopy for endometrial cancer. 2004-2005
5. Dr C Roberts, Resident O &G: CIN 1, management and outcomes. 2005-2007
6. Dr K Daniels, Resident O &G: Laparoscopy for adnexal masses. 2005
7. Dr S Clarke, Resident Radiology: Risk of Malignancy index in adnexal masses. 2006-2007
8. Dr A Altman, Resident O &G: Incidence of GTD in Nova Scotia. 2006-2007
9. Dr B Al Kudmani, Resident O &G: LSIL/ ASCUS and HPV status. 2006-2007
10. Dr L McCarthy, Resident O & G: Condyloma and rates of high grade dysplasia. 2007-2008
11. Dr A Ball, Resident O &G: Factors in laparoscopic surgery for endometrial cancer. 2007-2008
Presentations and Papers:
Presentations:
1. Complications of Surgical Abortion, Grand Rounds Dept. of Obs/Gyn, Dalhousie; April 1994
2. Laparoscopic Hysterectomy, Grand Rounds Dept. Obs/Gyn, Dalhousie; Dec. 1994
3. Palliative Care in Gynecology Oncology, Grand Rounds Dept. Obs/Gyn, Dalhousie; Feb. 1995
4. Gestational Trophoblastic Neoplasia, Grand Rounds Dept Obs/Gyn, Dalhousie; March 1995
5. Kallmann's Syndrome, Grand Rounds Dept. Obs/Gyn, Dalhousie; June 1995
6. Endometrial Hyperplasia, Grand Rounds Dept. Obs/Gyn, Dalhousie; Oct.1995
7. Cord Prolapse, Grand Rounds Dept. Obs/Gyn, Dalhousie; Dec.1995
8. Congenital Cardiac Disease in Pregnancy, Grand Rounds Dept. Obs/Gyn, Dalhousie; Jan 1996
9. Fetal Nucal Translucency Screening for Aneuploidy, Maternal-Fetal Medicine Journal Club; Feb. 1996
10. Does Amniotomy Increase the Incidence of Cord Prolapse? Annual Resident Research Day, Dept. Obs/Gyn, Dalhousie University; May 1996
11. Does Amniotomy Increase the Incidence of Cord Prolapse? Atlantic Society of Obstetrics and Gynecology, Charlottetown, PEI. Sept 1996
12. Challenges Facing the Discipline, Fiftieth Anniversary of Residency Program, Dalhousie University, Halifax, NS; Oct. 1996
13. Surgical Approaches to Early Cervical Cancer, Grand Rounds Dept. Obs/ Gyn, Winnipeg; Sept 1997
14. Platinum Based Chemotherapy in Uterine Papillary Serous Carcinoma, Research Day, Manitoba Cancer Treatment Research Foundation; Feb. 1998
15. Familial Ovarian Carcinoma, Grand Rounds Dept. Obs/ Gyn, Winnipeg; May 1998
16. Platinum Based Chemotherapy in Uterine Papillary Serous Carcinoma, SOGC, Victoria BC, June 1998
17. Surgical Criteria for No Adjuvant Therapy in Uterine Papillary Serous Carcinoma, Research Day Manitoba Cancer Treatment Research Foundation; Feb. 1999
20. High Risk Endometrial Carcinoma, Grand Rounds Dept. Obs/Gyn, Dalhousie University; March 1999
21. Surgical Criteria for No Adjuvant Therapy in Uterine Papillary Serous Carcinoma, Felix Rutledge Society, Winnipeg; June 1999
22. Uterine Leiomyosarcoma; A 21 year review, Felix Rutledge Society, Winnipeg; June 1999
23. Surgical Criteria for No Adjuvant Therapy in Uterine Papillary Serous Carcinoma, SOGC, Ottawa; June 1999
24. Familial Ovarian Cancer, Oncology Rounds QEII, Halifax; Dec 1999
25. Familial Ovarian Cancer, Update for Specialists, Dept. Obstetrics and Gynecology Dalhousie University, Halifax; April 2000
26. Advanced Cervical Cancer, Oncology Rounds QEII, Halifax; June 2000
27. High Risk Endometrial Cancer, Oncology Rounds QEII, Halifax; Oct 2000
28. Controversies in Colposcopy, Grand Rounds Dept. Obs/Gyn Dalhousie University; Oct 2000
29. Gynecologic Cytology; the Colposcopists Point of View, Maritech 2000, Dartmouth; Nov 2000
30. Familial Breast Ovarian Cancer, Senior Resident Weekend, Montebello Quebec, Feb 2001
31. Surgical Management of Ovarian Cancer, Visiting Professor, Saint John NB, Feb 2001
32. Standards for Colposcopy, Society of Canadian Colposcopists, St. Johns NF, June 2001
33. Stump the Professor, Faculty, SOGC, St John NF, June 2001
34. Recurrent Cervical Cancer: We Are Aggressive Enough, Gynecologic Oncologists of Canada, Montreal, April 2002
35. The Impact of Bethesda 2001 and New Screening Techniques on Colposcopy, Maritime Pathology and Laboratory Conference, Halifax, April 2002
36. New Screening Techniques Implications for Practice, SOGC, Winnipeg MB, June 2002
37. Who should do colposcopy? Subspecialist vs Generalist, SCC, Charlottetown, June 2003
38. Vulvar lesion Management, SOGC, Charlottetown, June 2003
39. Current Management of Ovarian Cancer, Saint John NB, Nov 2003
40. Management Options in CIN 1, SOGC Ontario Meeting, Dec 2003
41. VIN Etiology, Diagnosis, Colposcopy and Treatment, SOGC, Edmonton AB, June 2004
42. Recurrent CIN post treatment, Colposcopic patterns and therapy, SOGC Edmonton AB, June 2004
43. Alternative Modalities in Gynecologic Oncology, GOC, Edmonton AB, June 2004
44. Management Options in CIN 1, SCC Sub-specialty Session SOGC, Edmonton AB June 2004
45. The Effect of Loop Electrical Excision Procedure on Future Pregnancy Outcome. Samson SA, Bentley JR, Fahey JT, McKay DJ, Gill, GH. (supervising author) SOGC, Edmonton AB, June 2004
46. Ovarian Cancer CME, Dartmouth NS, Oct 2004
47. Management Options in CIN 1, SOGC Ontario Meeting, Nov 2004
48. Ovarian Cancer CME, Liverpool NS, Nov 2004
49. HPV testing in the Colposcopy Clinic, SOGC Ontario Meeting, Nov 2004
50. The Use of Liposomal Doxorubicin in Ovarian Cancer, Halifax NS, April 2005
51. LEEP and pregnancy outcome. World Congress of Colposcopy and Cervical Pathology, Cancun Mexico, June 2005
52. LEEP and Pregnancy outcome, SOGC, Quebec City, Quebec, June 2005
53. Whats your Diagnosis, Interactive Colposcopy, Quebec City, Quebec, June 2005
54. LEEP and Pregnancy outcome, Atlantic Society of O and G, Cornerbrook NL, Sept 2005
55. Gestation Trophoblastic Disease in Nova Scotia Atlantic Society of O and G, Cornerbrook NL, Sept 2005
56. Colposcopy Standards in Nova Scotia, SOGC, Vancouver BC, June 2006
57. Linking Human Papillomavirus to the practice of Immunization Halifax NS, Sept 2006
58. Linking Human Papillomavirus to the practice of Immunization Kentville NS, Oct 2006
59. Linking Human Papillomavirus to the practice of Immunization Yarmouth NS, Oct 2006
60. HPV and Immunization, Grand Rounds Charlottetown PEI Nov 2006
61. HPV and Vaccination, Why and for Whom, Grand Rounds Saint John Regional Hospital NB December 2007
62. HPV and Immunization, Sydney GP’s Dec 2006
63. HPV Pathogenesis and Epidemiology, Atlantic Canada HPV Forum, Halifax, Feb 2007 (Meeting Chairperson)
64. Contemporary Management of Ovarian Cancer , Saint John NB, February 2007
65. Management of Recurrent Ovarian Cancer, Fredricton NB, March 2007
66. To Leep or not, Consequences of treatment and presentation of cases, SCC Update SOCG Banff, March 2007
67. HPV Vaccination: Whats the Buzz?? Department of Obstetrics and Gynecology GP refresher, April 2007
68. Ultrasound and Risk of Malignancy Index in patients with Adnexal Masses, Clarke S, Bentley J Radiology Resident Research Day, March 2007 (supervising author)
69. HPV epidemiology and vaccination. Public Health Nurses PEI May 2007
70. Colposcopy case studies SCC PG1 SOGC Ottawa, June 2007
71. Risk Of Malignancy Index In The Evaluation Of Patients With Adnexal Masses In Nova Scotia Clarke S, Bentley J, GOC Ottawa, June 2007 (supervising author)
72. Prevention of Cervical Cancer through Vaccination, Primary Care Updates, Kingston Ontario, Sept 2007
73. Transplantation and Gynecological Cancer. Transplant Atlantic, Halifax, Oct 2007 (invited)
74. Contemporary Management of Ovarian Cancer. Barrie, Ontario, Nov 2007
75. Contemporary Management of Ovarian Cancer. Oncology Rounds Mississauga, Nov 2007
76. Update on Ovarian Cancer. Specialist Update in Obstetrics and Gynecology, Halifax March 2008
77. Prevention of Cervical Cancer and Other HPV related Diseases, Dalhousie CME, 10 sites Feb- June 2008
78. Management Algorithms for Dysplasia, Colposcopy Workshop, Halifax, May 2008
79. HPV, HPV testing and vaccination in the clinic, Colposcopy Workshop, Halifax, May 2008
80. Improving your Colposcopy accuracy, Colposcopy Workshop, Halifax, May 2008
81. Colposcopic features of Low Grade Lesions, 6th World Congress in Colposcopy, Gynecologic Oncology and Breast Cancer, Toluca, Mexico, June 2008 (invited)
82. Canadian Algorithms for the Management of Cervical Dysplasia. 6th World Congress in Colposcopy, Gynecologic Oncology and Breast Cancer, Toluca, Mexico, June 2008 (invited)
83. HPV Genotypes In Cervical Dysplasia; Preliminary Results from the TPAPT study. 6th World Congress in Colposcopy, Gynecologic Oncology and Breast Cancer, Toluca, Mexico, June 2008 (invited)
84. Management Patterns and cost of care for women with abnormal cervical cytology treated in Canadian Colposcopy clinics. Mayrand MH, Goggin P, Rash B, Bentley J, Brisson M, Fung-Kee-Fung M, Gathage P, Gilca V, Murphy J, Duval B. SOGC Calgary June 2008 (Contributing Author)
85. Management of Screening Abnormalities: The Canadian Perspective. SOGC Calgary June 2008
86. Intraperitoneal Chemotherapy for Ovarian Cancer. Atlantic Society of Oncology, Charlottetown PEI June 2008 (invited)
87. Colposcopy Cases. Atlantic Society of Obstetrics and Gynecology, St Johns NF September 2008
88. Triage using repeat ASCUS or LSIL pap smears; Is there any difference between categories? Bentley JR, Bentley B, Ratnam S, IFCPC Auckland New Zealand October 2008
89. Colposcopy Case Presentations: Interactive Session, IFCPC Auckland New Zealand October 2008
90. Gynecological malignancies for GP’s, Videoconference Dal CME March 2009
91. Management of High Grade Cervical Dysplasia, SCC Basic Colposcopy Course, June 2009
92. New Biomarkers in the triage of CIN 2+, SCC Post Graduate Course SOGC, June 2009
93. The North American Perspective, IFCPC Symposium, FIGO Cape Town, South Africa Oct 2009 (invited)
94. Management of Recurrent Ovarian Cancer, Moncton NB December 2009
95. Eurogin Update; Coposis online presentation. March 2010
96. HPV Vaccination Facts and Controversies, Specialists Update Dept of Obstetrics and Gynecology March 2010
97. Advances in Cervical Cancer, Halifax NS, April 2010
98. Advances in Cervical Cancer, Toronto Ontario April 2010
99. Management of Recurrent Ovarian Cancer, Saint John NB April 2010
100. Approaches to Endometrial Cancer, Saint John NB, April 2010
101. Management of Dysplasia SCC Basic Colposcopy Course, Halifax, SOGC June 2010
102. Management of Cervical Lesions, SOGC International Symposium, Montreal QC June 2010
103. Advances in Cervical Cancer, Primary Care Updates Halifax June 2010
Posters:
1. Does Amniotomy Increase the Incidence of Cord Prolapse? 52nd Annual Clinical Meeting SOGC, Quebec City; June 1996.
2. Surgical Criteria for No Adjuvant Therapy in Uterine Papillary Serous Carcinoma, Highlighted Poster, Society of Gynecologic Oncology, San Francisco; March 1999
3. Adjuvant therapy in Stage 1 Uterine Leiomyosarcoma: A Retrospective Review. GOC Annual scientific Meeting, St Johns NF; June 2001
4. Facilators and Obstacles in Randomized Trials- Experience from a randomized clinical trial of immediate treatment (IT) versus Colposcopic follow-up of biopsy proven cervical intraepithelial neoplasia grade 1 (CIN 1). Elit L, Zeferino C, Roth P, Bentley J, Finch T, Julian J, Lytwyn A, Mahoney J, Sellors J, Levine J. IPC Vancouver May 2005
5. Efficacy of Pegylated Liposomal Doxorubicin (PLD) plus Carboplatin in patients with partially sensitive relapsing advanced ovarian cancer. Power P, Stuart G, Oza A, Provencher D, Bentley JR, Miller W, Lee U, Plante M, Pouliot J-F, IGCS Santa Monica October 2006
6. The Incidence of Gestational Trophoblastic Disease in Nova Scotia. Altman A, Bentley B, Murray SC, Bentley J, GOC Ottawa June 2007
7. Biomarker testing in cervical cancer screening: Preliminary results from a Canadian multicentre study Fontaine D, Bentley J, Escott N, Ghatage P, Holloway G, Bartellas E, Kum N, Gadag V, Lear A,Coutlee F, Ratnam S for the TPAPT Study Group. Eurogin Monaco October 2007
8. Efficacy of Pegylated Liposomal Doxorubicin (PLD) plus Carboplatin in patients with partially sensitive relapsing advanced ovarian cancer. Power P, Stuart G, Oza A, Provencher D, Bentley JR, Miller W, Lee U, Plante M, Pouliot J-F, ESGO Berlin Germany October 2007
9. Colposcopy to detect CIN2+ in women with external genital warts. Bentley JR, McCarthy L, Hudson J, Grimshaw R, IFCPC Auckland New Zealand October 2008
Publications:
1. Laparoscopic Assisted Vaginal Hysterectomy-A Pilot Project A.W. Zilbert, J.R. Bentley, S.A. Farrell, Heidi Clough-McClare JSOGC 1996;18;2,131-140.
2. Surgical Criteria for No Adjuvant Therapy in Uterine Papillary Serous Carcinoma. James R. Bentley, Robert J. Lotocki, Mark S. Heywood, and Garry V. Krepart. Gynecol Oncol 1999;72:456 (in abstract)
3. Treatment of Uterine Papillary Serous Carcinoma with Platinum-Based Chemotherapy. James R. Bentley, Robert J. Lotocki, Mark S. Heywood, and Garry V. Krepart. Gynecol Oncol 1999 72:510 (in abstract)
4. Optimal Management for Surgical Stage 1 Serous Cancer of the Uterus, Elit, L.; Kwon, J.; Bentley, J.; Trim, K.; Ackerman, I.; Carey, M. Gynecol Oncol 2004; 92; 240-246
5. The Effect of Loop Electrical Excision Procedure on Future Pregnancy Outcome. Samson SA, Bentley JR, Fahey JT, McKay DJ, Gill, GH. Obstetrics and Gynecology 2005; 105; 325-332
6. Complementary and Alternative Medicine in Gynaecologic Oncology, McKay DJ, Bentley JR, Grimshaw RN. JSOGC 2005; 27; 562-568
7. Guidelines for Training Requirements in Colposcopy and its Related Treatment Modalities. McFaul SM, Bentley JR, Bertrand MA, Brydon L, Bryson P et al JSOGC 2006; 28; 314-316
8. Gemcitabine Plus Carboplatin Compared with Carboplatin in Patients with Platinum-Sensitive Recurrent Ovarian Cancer: An Intergroup Trial of the AGO-OVAR, the NCIC CTC, and EORTC GCG. Pfisterer J, Plante M, Vergote I, DuBios A, Hirtle H, Lacave A, Wagner U, Stahle A, Stuart G, Rainer K, Olbricht S, Khum W, Bentley J, Jackisch C, Luck H, Rochon J, Zimmerman AH, Eisenhauer E. JCO 2006; 24;4699-4707
9. Efficacy of Pegylated Liposomal Doxorubicin (PLD) plus Carboplatin in patients with partially sensitive relapsing advanced ovarian cancer. Power P, Stuart G, Oza A, Provencher D, Bentley JR, Miller W, Lee U, Plante M, Pouliot J-F, IJGC 16(S3) 655 (in abstract)
10. Cervical Cancer Screening Abnormalities, chapter author in Contemporary Knowledge and Issues in Cervical Cancer Screening and Prevention in the Era of HPV Vaccination: The Canadian Context. CD Available to GOC, CAIRE members.
11. Maternal Age-Related Rates of Gestational Trophoblastic Disease. Altman AD, Bentley BB, Murray SM, Bentley JR, Obstet Gynecol 2008 112:244-250
12. Optimization of primary and secondary cervical cancer prevention strategies in an era of cervical cancer vaccination: A multi-regional health economic analysis. Raina M Rogoza, Nicole Ferko, James Bentley, Chris JLM Meijer, Johanes Berkof, Kung-Liahng Wang, Levi Downs, Jennifer S Smith, Eduardo Franco, Vaccine (2008) 26S:F46-F58
13. Risk of Malignancy index in the evaluation of patients with adnexal masses. Clarke S E, Grimshaw R, Rittenberg P, Keiser K, Bentley J; J Obstet Gynecol Can (2009) 31: 440-445
14. Initial Evaluation and Referral Guidelines for management of pelvic/ovarian masses. Le T, Giede C, Salem S, Lefebvre G, Rosen B, Bentley J et al. J Obstet Gynaecol Can. 2009 Jul;31(7):668-80
15. Clinical Performance of the PreTect HPV-Proofer E6/E7 mRNA Assay in Comparison with That of the Hybrid Capture 2 Test for Identification of Women at Risk of Cervical Cancer. Ratnam S, Coutlee F, Fontaine D, Bentley J et al. J Clin Microbiol 2010 Aug;48 (8):2779-85
Non Peer reviewed publications:
Journal Review:
Journal of Pelvic Medicine and Surgery 2006, 2 articles
Journal of Pelvic Medicine and Surgery 2007, 2 articles
Journal of Pelvic Medicine and Surgery 2008, 1 article
Other:
Editor newsletter SCC June 2007 to July 2009
External Review Division of Gynecologic Oncology, University of Ottawa, Oct 2009
Royal College External Review, Division of Gynecologic Oncology, University of Manitoba, June 2010
Thesis Reviewer:
1. Halfyard B . ASC triage using HPV testing. Memorial University, Newfoundland Masters Thesis 2008
Prizes:
1. Second Prize Annual Resident Research Day Department of Obstetrics and Gynecology, May 1996; Does Amniotomy Increase the Incidence of Cord Prolapse?
2. Second Prize Research Day, Manitoba Cancer Treatment Foundation, Feb. 1998; Treatment of Uterine Papillary Serous Carcinoma with Platinum-Based Chemotherapy.
|